• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$33.38 $0.05 (0.15%)

REAL-TIME: Last trade at

Forest Laboratories, Inc.

NYSE:FRX

Jump to this page for:

Related Resources

Synergy Pharma: Best Hidden Gem Of 2012

5/24/2012 by Seeking Alpha

Earnings Scorecard: Forest Labs - Analyst Blog

5/2/2012 by Nasdaq

Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeut

4/27/2012 by Nasdaq

Mylan Beats, Reaffirms Outlook - Analyst Blog

4/26/2012 by Nasdaq

Yet Another Delay for Forest Labs - Analyst Blog

4/24/2012 by Nasdaq

Forest Laboratories Beats on Both Top and Bottom Lines

4/18/2012 by DailyFinance

3 Stocks to Get on Your Watchlist

4/18/2012 by DailyFinance

Forest Labs 4Q Net Falls 40% As Lexapro Patent Expires; Has Upbeat Year View

4/17/2012 by Smart Money

Forest Hit by Lexapro Generics - Analyst Blog

4/17/2012 by Nasdaq

Forest Buys Bystolic Rights - Analyst Blog

4/9/2012 by Nasdaq

Teva Active on the Generics Front - Analyst Blog

4/5/2012 by Nasdaq

Forest Laboratories Buys Blood Pressure Drug Bystolic From Janssen For $357 Million

4/2/2012 by Smart Money

Delay in Forest Drug FDA Action Date - Analyst Blog

3/30/2012 by Nasdaq

Forest-Janssen Sue Generic Players - Analyst Blog

3/16/2012 by Nasdaq

Teva Launches Generic Lexapro - Analyst Blog

3/15/2012 by Nasdaq

Teva Receives FDA Approval For Generic Lexapro For Adults

3/14/2012 by Smart Money

Watson Pharma Seeks FDA Approval of Generic Version Of Bystolic

3/14/2012 by Smart Money

Forest Candidate Scores in Study - Analyst Blog

3/13/2012 by Nasdaq

CEO Gaffe of the Week: AstraZeneca

3/10/2012 by DailyFinance

Positive News on Forest's Pipeline - Analyst Blog

3/6/2012 by Nasdaq

Mylan Launches Generic Lexapro - Analyst Blog

3/1/2012 by Nasdaq

A Leap of Faith: Teva Pharmaceutical

2/29/2012 by DailyFinance

FDA: Forest Labs Lung Drug Effective For COPD; Raises Concerns

2/21/2012 by Smart Money

A Hidden Reason Forest Laboratories' Future Looks Bright

2/17/2012 by DailyFinance

Teva Delivers in 4Q - Analyst Blog

2/16/2012 by Nasdaq

UPDATE: Teva 4Q Net Drops 34% On Acquisition Costs; Sales Up 28%

2/15/2012 by Smart Money

Meet the Branded-Generic-OTC Drugmaker

2/15/2012 by DailyFinance

These Single-Digit P/Es Are Value Traps

2/13/2012 by DailyFinance

Positive Results on Forest/Gedeon Drug - Analyst Blog

2/9/2012 by Nasdaq

The Zacks Analyst Blog Highlights: Citigroup, JPMorgan Chase, Goldman Sachs Group, Bank of America a

1/18/2012 by Nasdaq

Opening View: DJIA Pointed Higher on China GDP; Financials in the Earnings Spotlight

1/17/2012 by Nasdaq

Forest Beats, Ups View - Analyst Blog

1/17/2012 by Nasdaq

Forest Laboratories Beats Analyst Estimates on EPS

1/17/2012 by DailyFinance

Something to Watch at Forest Laboratories

1/13/2012 by DailyFinance

Earnings Preview: Forest Labs - Analyst Blog

1/13/2012 by Nasdaq

Ring in Generics in 2012 and Beyond - Analyst Blog

12/29/2011 by Nasdaq

Teva Provides In-Line 2012 Outlook - Analyst Blog

12/23/2011 by Nasdaq

Teva Sees Sales, Profit Up In 2012; Authorizes $3 Billion Stock Buyback

12/21/2011 by Smart Money

UPDATE: Teva Sees Sales, Profit Up In 2012; Authorizes $3 Billion Stock Buyback

12/21/2011 by Smart Money

Zacks Bull and Bear of the Day Highlights: Smithfield Food, BHP Billiton, Pfizer, Eli Lilly and Fore

12/20/2011 by Nasdaq
See More Articles...